Boston University, US
Rhoda Au is Professor of Anatomy & Neurobiology, Neurology and Epidemiology at Boston University Schools of Medicine and Public. She also currently serves as Director of Neuropsychology at the Framingham Heart Study, where she has been involved in research related to cognitive aging and dementia since 1990. Most recently, she has been exploring the potential of cognitive digital biomarkers and how “big data” analytics can better inform our understanding of Alzheimer’s disease pathways and treatment. Beyond Framingham, Dr. Au is focused on building multi-sector ecosystems to enable solutions for chronic disease prevention generally and optimizing brain health specifically and to move the primary focus of health technologies from precision medicine to a broader emphasis on precision health.
Actress, activist on Traumatic Brain Injury, Ambassador Women’s Brain Project, US
Chéri Ballinger is a professional actress, fashion model, and movie producer who has appeared in numerous films, TV shows, and commercials and print advertisements worldwide. She got her start in film while being discovered as a young girl and placed in the iconic Disney film “The Parent Trap” in 1998. She has worked in film steadily ever since. For nearly ten years, she was the official spokesmodel of Sun Labs/Giselle Cosmetics, representing them in all global media and events. Her dedication, optimism, and strong work ethic allowed her to earn a Bachelor’s Degree from California State University while simultaneously working around the world. In 2014, Chéri suffered from a horrific accident that left her with a severe traumatic brain injury (TBI). After years of grueling physical and speech therapy, as well as the grim prospect that she would not be able to have a full life again, Chéri overcame all the odds against her. With her passion for her second chance at life and her effervescent personality, she is now back to work in Hollywood primarily producing movies while also focusing on her international philanthropy efforts. Her latest feature film is the much anticipated “Roe v Wade” to be released in mid-2019. While currently working on a number of other incredible films, she’s also now producing an exciting feature entitled “Lazarus”. Chéri is focused on producing films that bring both entertainment and positive messages to an international audience. In addition, she is now an international speaker and the official ambassador for the Women’s Brain Project based in Switzerland.
Beatrice Beck Schimmer
Director of the Medical University of Zurich, Switzerland
University of Arizona, US
Dr. Roberta Diaz Brinton leads the Center for Innovation in Brain Science at the University of Arizona whose mission addresses neurodegenerative diseases of aging, Alzheimer’s, Multiple Sclerosis, Parkinson’s and ALS.
Brinton is an internationally recognized expert in the systems biology of Alzheimer’s disease and is developing the first regenerative therapeutic to regenerate the degenerated brain. Her analyses focused on the brain at greatest risk for Alzheimer’s, the aging female brain. Brinton’s research has shown that the aging brain undergoes a set of sequential bioenergetic and neuro-immune transitions that can lead to neurodegenerative disease. Further, her findings show that the sex difference in Alzheimer’s disease is not because women live longer than men, as commonly thought, but rather because the disease starts earlier in the female brain. Her insights into the transition states of the aging brain provide therapeutic opportunities to prevent, delay and treat neurodegenerative disease.
Brinton earned her Ph.D. as an NIH Predoctoral Fellow at the University of Arizona and went on to Rockefeller University as an NIH Postdoctoral Fellow. Subsequently, Brinton joined the University of Southern California faculty where she was Professor of Molecular Pharmacology, Biomedical Engineering and Neurology. Currently, Brinton is Professor of Pharmacology, Neuroscience and Neurology at the University of Arizona College of Medicine and Director of the Center for Innovation in Brain Science. She serves on the Alzheimer’s Drug Discovery Foundation Board of Governors and has serves on National Institute of Health scientific advisory boards and review panels. Her research has been continuously funded by the National Institutes of Health and for over two decades by the National Institute on Aging.
Brinton’s scientific research and STEM education endeavors have been recognized by numerous awards including Scientist of the Year by the Alzheimer’s Drug Development Foundation, Goodes Prize for Excellence in Alzheimer’s Drug Discovery, National Institute of Aging MERIT Award, the US Presidential Citizens Medal in 2010 and Ten Best Minds by US News and World Report.
University of Zurich, Switzerland
International Corporate Affairs Pain Platform and Alzheimer’s disease Eli Lylli, Italy
Vice-Director General, Swiss Federal Office of Public Health, Ambassador for Global Health
Tania Dussey-Cavassini combines experience in global health, management consulting, executive education, diplomacy and law enforcement. Until July 2017, she was Ambassador for Global Health and Vice-Director General of the Swiss Federal Office of Public Health, in charge of International Affairs.
From 2006 to 2012, Tania worked at IMD, ranked #1 worldwide by the FT in Executive Education. As Director of Partnership Programs, she was responsible for developing IMD’s custom programs for multinational companies, designing transformational learning and development initiatives that blend capability building with business impact. Since 2010, she is also an adviser to the United Nations Institute for Training and Research (UNITAR). Parallel to her official function, Tania helps women executives find their own voice and coaches them in career transitioning and leadership. Prior to these activities, Tania held diplomatic assignments for Switzerland in Paris, Bern, Moscow and Geneva. She started her career in 1991 as a lawyer working in the realm of international criminal matters and extraditions proceedings.
Tania is a Harvard Fellow (2012-2013). She was educated in management at IMD (2006), in law at the University of Lausanne (1989), and music at the University of Music Lausanne (1988), Switzerland. She is a certified coach with The Actor’s Institute, New York (2010).
Tania serves on the Board of Directors of the Here-Geneva Foundation (Humanitarian Exchange and Research Centre). She is member of the Advisory Board of The Women’s Brain Project, promoting gender-based research.
Geoffrey Beene Foundation Alzheimer’s initiative Women’s Brain Project
University of Lille. Vice-President of the European Stroke Organization, France
Prof. Charlotte Cordonnier, MD, PhD, is a neurologist specialised in stroke medicine. Appointed as Professor of Neurology at the Lille University (France) in 2012, she is the head of the department of Neurology & Stroke centre of the Lille University Hospital. Her research interests are intracerebral haemorrhages (including microbleeds) both in the setting of stroke and dementia, acute management of stroke, and stroke specificities in women. She is the director of the Lille Haemorrhagic Stroke research program inside the INSERM U1171. She has been a member of the Institut Universitaire de France since 2015, and serves as vice-president of the European Stroke Organisation (2016-2020). She is one of the founding members of the Women Initiative for Stroke in Europe (WISE).
Reader in Forensic & Neurodevelopmental Psychiatry, UK
Ellpha Project – Co-Founder, US
Stephanie is the CEO and co-founder of Ellpha, the first Artificial Intelligence program designed to detect and help fight gender bias in content, systems or processes.
She trained as an Aeronautics engineer in Ecole Centrale Paris and has always had a passion for science, data and technology. After working in the Aeronautics industry, she spent 20 years in the fmcg industry leading global strategic insights teams and understanding the consumers psychology and behaviours behind market growth.
The science around unconscious bias resonates with Stephanie’s own life experience as a daughter, sister, mother and passionate manager & mentor of women in the workplace.
In 2017 this instilled her drive to use data and AI to accelerate reaching gender parity and co-found the ellpha project.
Author of the book “Doing Harm”, US
Maya Dusenbery is an American journalist and author of the book Doing Harm: The Truth About How Bad Medicine and Lazy Science Leave Women Dismissed, Misdiagnosed, and Sick. She is editorial director of the award-winning site Feministing.com and was formerly a fellow at Mother Jones magazine and a columnist at Pacific Standard. Her writing has appeared at Slate, The Atlantic, HuffPost, Cosmopolitan, Popular Science, and more. Before becoming a full-time writer, she worked at the National Institute for Reproductive Health. A Minnesota native, she is currently based in Portland, Oregon.
Senior vice President of Neuroscience-20, Verticai Consulting and Ventures, Switzerland
Christoph Ebell is an entrepreneur, science diplomat, technology consultant and transformation strategist. He was born in Bern in 1972. He first studied physics, then humanities and graduated in Bern and Chicago. After a research stay in Cambridge (USA), he worked for the Swiss government’s innovation agency CTI, then for the Swiss Interior, Economy, and Foreign Affairs Departments and was transferred to head the Science Section at the Swiss Embassy in Washington, D.C. Back in Switzerland, he worked for the Human Brain Project, a multidisciplinary EU project in computer-based brain research and the largest of its kind in Europe, for the last 3 years as its Executive Director. In 2018 Chris Ebell established a consulting firm for technology projects and venture capital, and is mandated as COO of a German software company for next generation High Performance Computing. He speaks frequently at international events. He is based in Geneva, Switzerland.
Maria Teresa Ferretti
Chief Scientific Officer Women’s Brain Project, Switzerland
After growing up in Sardinia (Italy) my studies led me to Spain, England, Canada and finally Switzerland.
Here I am currently a junior group leader at University of Zurich working on biomedical research in the field of Alzheimer’s disease.
My goals are to help finding a cure for this devastating disease and to support the lives of Alzheimer’s patients and caregivers. It was shocking to learn that both are overwhelmingly women. Therefore I enthusiastically joined the Women’s Brain Project organization as a vehicle to promote gender-related science and advocate for actions in support of caregivers.
University of British Columbia, Canada
Liisa Galea is a Professor in the Department of Psychology, a member of the Centre for Brain Health, Director of the Graduate Program in Neuroscience, and a Scientific Advisor at Women’s Health Research Institute at the University of British Columbia. My research investigates how sex hormones influence brain health and disease in both females and males. The main goal of my research is to improve brain health for women and men by examining the influence of sex and sex hormones on normal and diseased brain states such as depression and Alzheimer’s disease.
Head of translational Science IDORSIA Pharmaceuticals, Switzerland
Harvard School of Medicine, US
Nouchine Hadjikhani, MD, PhD, is Associate Professor in Radiology at Harvard Medical School, where she directs the Neurolimbic Research Laboratory. She is also an Assistant in Neurosciences at the Massachusetts General Hospital and Visiting Professor at GNC, Gothenburg University, Sweden. She is an author of 105 peer-review articles and 14 books, book chapters and other publications.
She has been doing brain imaging for more than twenty years, using neuroanatomy, histology, Positron Emission Tomography (PET), Magnetic Resonance Imaging (MRI), magnetoencephalography (MEG) as well as behavioral methods, including eye-tracking, to study the normal and the diseased brain. Her research stems from her interest of the visual system and include conditions such as migraine and autism.
Commissioner for Women’s Health FDA, US
Parteners MS Center Brigham and Women’s Hospital Harvard Medical School, US
Dr. Maria Houtchens is an Associate Professor at Harvard Medical School in Boston, MA. Dr. Houtchens received her M.D. degree from the University of Utah School of Medicine and completed her neurology residency at Harvard. She also received a Masters of Medical Sciences degree from Massachusetts Institute of Technology/Harvard School of Public Health. She finished a fellowship in Multiple Sclerosis and Demyelinating Diseases at Partners Multiple Sclerosis Center, Brigham and Women’s Hospital (Dr. Howard Weiner) and established herself as an independent clinical researcher and an expert in the field of Women’s Neurology as it relates to MS patients. She is a neurologist at the Brigham and Women’s Hospital, and a Director of Women’s Health Program at Ann Romney Center for Neurologic Diseases/Partners MS Center. She is well known nationally and internationally for her work in women’s health, and has published numerous research and review articles on subject of pregnancy management and women’s health in multiple sclerosis, as well as trained numerous residents and fellows in this field. Her current research focus is on establishing MS disease-state pregnancy registries, understanding the incidence and prevalence of depression and inflammation correlates in post-partum MS patients, and assuring equitable and equal access to care for MS patients regardless of gender.
Institute for Ethics and Emerging Technologies, Trinity College in Hartford, Connecticut, US
James Hughes Ph.D. is a bioethicist and sociologist who serves as the Associate Provost for the University of Massachusetts Boston (UMB), and as Senior Research Fellow at UMB’s Center for Applied Ethics. He holds a doctorate in Sociology from the University of Chicago where he taught bioethics at the MacLean Center for Clinical Medical Ethics. Since then Dr. Hughes has taught health policy, bioethics, medical sociology and research methods at Northwestern University, the University of Connecticut, and Trinity College. Dr. Hughes is author of Citizen Cyborg: Why Democratic Societies Must Respond to the Redesigned Human of the Future (2004) and is co-editor of Surviving the Machine Age: Intelligent Technology and the Transformation of Human Work (2017). In 2005 Dr. Hughes co-founded the Institute for Ethics and Emerging Technologies (IEET) with Oxford philosopher Nick Bostrom, and since then has served as its Executive Director. Dr. Hughes serves as Associate Editor of the Journal of Evolution and Technology, and as co-founder of the Journal of Posthuman Studies. Dr. Hughes speaks on medical ethics, health care policy and future studies worldwide.
Singularity University, Women’s Brain Project
Head of Strategy and Future Media at the European Broadcasting Union until November 2014, she earned a Ph.D (summa cum laude) in 2015, focusing on Ethics and Emerging Technologies.
Member of the International Academy of Television Arts and Sciences, she’s a BAFTA guru and a Senior Advisor at Singularity University.
International speaker and event moderator, she has curated five editions of TEDxTransmedia and nine European Broadcasting Union Summits.
On December 2017 she will curate and host the first edition of TEDxCarouge.
Currently, she studies the future, she works on ethics and emerging technologies, she teaches “Emerging Media” at Webster University Geneva and is visiting professor, at Jinan University, in Guangzhou, China, teaching Virtual reality storytelling and VR journalism.
I have investigated and written on the topic of ethics and exponentially growing technologies in both my Ph.D. thesis and in my ongoing book, entitled Exponential Ethics.
Here’s an article I wrote on the subject.
Ethics must keep up with the exponential progress of technology; it must leapfrog and facilitate public debates among influential contemporary thinkers, scientists, artists, engineers, philosophers, and science-
This will be the most pioneering decade in history.Exponential technologies will lead to exponential innovation.
We should strive to take this journey, conscious of the risks we are facing, and raise a call to action for openly discussing the social repercussions these technologies could have if left only to their “makers”—a call to action to “Reboot Ethics.”
Executive Director Mary Horrigan Connors Center for Women’s Health and Gender Biology, Vice Chair for Research, Department of Psychiatry Brigham and Women’s Hospital
Dr. Joffe is the Paula A. Johnson Associate Professor of Psychiatry in the Field of Women’s Health at Harvard Medical School, Executive Director of the Connors Center for Women’s Health and Gender Biology at Brigham & Women’s Hospital, and Director of the Women’s Hormones and Aging Research Program. Dr. Joffe is an experienced clinician and clinical reproductive neuroscientist in women’s aging and mental health. Her work focuses on the mechanisms, course, and treatment of menopausal symptoms (hot flashes, insomnia, depression, fatigue) in healthy women and breast cancer survivors. For 20 years, she has been funded by the NIH and pharmaceutical companies. The Connors Center goal is to ignite change in sex/gender medicine, including through their First-in-Women Precision Medicine Platform.
CNN Money, Switzerland
Amanda Kayne is a news anchor at CNNMoney Switzerland. In 2011 she joined Julius Baer as the communications face of the bank and to lead its global future trends initiative. Previously, the British native was a journalist for the BBC’s World Business report and a reporter for CNBC Europe. She began her career as a current affairs presenter for the news network Russia Today. She holds postgraduate diplomas in economics from the London School of Economics and in print journalism from the National Council for the training of Journalists UK.
Wyss Research Center Switzerland Women’s Brain Project
Director Interactive Robots and Media Lab MIT, US
Nikolaos Mavridis, PhD from the Massachusetts Institute of Technology (MIT), is an Academic and Consultant specializing in Robotics and Artificial Intelligence. He is the founder and director of the Interactive Robots and Media Lab (IRML), and has served as faculty at numerous institutions, including New York University (NYU) AD, the National Center for Scientific Research Demokritos, and others. His interests include intelligent robots, and especially verbal and non-verbal communication with robots, artificial intelligence, machine learning, and cognitive systems. He has served in numerous leadership and pro-bono positions, has been a TEDx Speaker four times, including Geneva and Athens, and is a member of the MIT Education Council and a mentor for the MIT Enterprise Forum.
Associate Director Alzheimer’s Prevention Clinic of Weill Cornell Medical College (WCMC), US
Dr. Lisa Mosconi, PhD, is Associate Professor of Neuroscience in Neurology at Weill Cornell Medical College (WCMC)/NewYork-Presbyterian Hospital, where she serves as Director of the Women’s Brain Initiative (WBI) research program and Associate Director of the WCMC Alzheimer’s Prevention Clinic. She also is an adjunct faculty member at the Department of Psychiatry at NYU School of Medicine, and at the Department of Nutrition at NYU Steinhardt School of Nutrition and Public Health. Dr. Mosconi is well known for her research on the early detection of Alzheimer’s disease in at-risk individuals, women in particular, using brain imaging techniques such as PET and MRI.
Associate Professor of Psychiatry Director, Women’s Mood Disorders Center Johns Hopkins School of Medicine, US
Dr. Payne is an Associate Professor of Psychiatry and the Director of the Johns Hopkins Women’s Mood Disorders Center. She received her medical degree from Washington University, completed her residency in psychiatry at Johns Hopkins and finished a fellowship in mood disorders through the Mood and Anxiety Disorders Program at NIH. In addition to providing outstanding clinical care for women with mood disorders, Dr. Payne conducts research into the genetic, biological, and environmental factors involved in postpartum depression and studies best practices for the management of mood disorders during and after pregnancy. She and her colleagues have recently identified two epigenetic biomarkers of postpartum depression and are working hard to replicate this work with NIH funding.
National Institute on Aging – Program director in the Division of Neuroscience, US
a patient living with Alzheimer’s disease, Sweden, Women’s Brain Project Ambassador
I am a woman of 43 years, who has been impacted by Alzheimer’s Disease for more than half of my life. My grandmother was buried during my first year and the autopsy showed Alzheimer’s. When I was 14 my father was affected by the disease and eventually died in 1999. His seven years younger brother died seven years after in the same disease.
I am thus committed to educate people about the Alzheimer’s Disease. With money from the Swedish Alzheimer Association I was able together with two other persons to make a film about being young and related to this disease.
I could not have imagined that seventeen years after my father’s death, I would receive the news that I was affected as well! l At the age of 39.
Unfortunately, I had to struggle at first to believed by doctors. When I passed most of the standardized tests, the doctors said that it was nothing to be worried about. I had to change doctors twice! But I finally got the help, when I got in contact with my father’s old retired doctor.. While the medical investigation was going on, I studied to be a health educator and managed a three-year education at the university.
My goal is to write about the many challenges of young-onset Alzheimer’s patients, and especially women’s encounters.
Read my stories @ “Sofia’s Corner“.>
University Hospital Barcelona, Spain
Patricia Pozo-Rosich MD PhD, is a specialist in Neurology. She is in charge of the Headache and Craniofacial Pain Clinical Unit at the University Hospital Vall d’Hebron in Barcelona, Spain; and the Headache Research Laboratory at the Vall d’Hebron Institute of Research (VHIR), which belongs to the Universitat Autonoma of Barcelona (UAB).
After winning the la Caixa, American Headache Society, Rio Hortega, EFNS, research awards she became a Fellow in Preclinical Research with Professor Silberstein at the Thomas Jefferson University in Philadelphia (PA, USA) and later on with Professor Goadsby both at Queen’s Square – University College London (UK)– and at the University of California at San Francisco (CA, USA).
She is the Coordinator of the Spanish Headache Study Group of the Spanish Neurological Society (cefaleas.sen.es), she is a member of the International Headache Society Board of Trustees, the International Headache Society Clinical Trials Guidelines Committee and the European Headache Federation Council.
She is the Editor for Headache for Revista de Neurologia, an Associate Editor of Frontiers in Neurology (Headache Medicine) and a member of the Editorial Advisory Board of The Journal of Headache and Pain.
Dr. Pozo-Rosich’s research focuses on better understanding the pathophysiology of migraine from a multidisciplinary approach using genetics, neuroimaging and electrophysiology. She has developed the Migraine Adaptive Brain research program. In this regard, she is a member of the International Headache Genetics Consortium. She has been awarded research grants from the la Caixa Foundation, Fondo de Investigaciones Sanitarias (ISCIII), la Marató TV3 Foundation, AGAUR, Mutual Medica and, the Migraine Research Foundation.
She has been the principal investigator of clinical trials in phases II and III.
She educates neurologists, other physicians and patients with the goal of improving the quality of life of patients suffering from headache and helping reduce the stigma of migraine. She is the founder and developer of the website in Spanish dedicated to headache www.midolordecabeza.org for patients and physicians which has more than 5,800 registered users and more than 25,000 facebook followers.
University of Zurich, Switzerland, Women’s Brain Project
Dr. med. Katrin Rauen is Fellow of the European Board of Neurology, consultant in Neurology and Psychiatry at the Department of Geriatric Psychiatry, University Hospital of Psychiatry Zurich “Burghölzli”, scientifically specializing on the neuroinflammatory and neurodegenerative long-term sequels following Traumatic Brain Injury (TBI). Dr. Rauen is holding a dual affiliation as Principal Investigator to the Institute of Regenerative Medicine at the University of Zurich (IREM), Switzerland, as well as to the Institute of Stroke and Dementia Research (ISD) at the Ludwig-Maximilians-University, Munich, Germany.
The overarching goal of Dr. Rauen´s research is to elucidate the pathophysiology of chronic TBI and to elucidate biomarkers to better stratify patients being at risk for posttraumatic cognitive decline, thereby setting the basis for new anti-inflammatory and anti-dementia therapy. Furthermore, she aims to implement neuro-psychiatric diagnostic algorithm to early identify patients being at risk for psychiatric disorders to support patients and their caregivers to adapt to the posttraumatic condition and to regain best quality of life despite the lifechanging brain trauma.
Dr. Rauen received her M.D. in 2011 from Ludwig-Maximilians-University, Munich, Germany and gained international experience at the UCL Queens Square Institute of Neurology, London, England, at Kaiser Permanente Rehab Center, Vallejo, California, USA, and at the University of Stellenbosch, South Africa. Her doctoral thesis Influence of vasopressin receptors and aquaporins on secondary brain injury following experimental TBI at Professor Plesnila´s laboratory at LMU Munich was honored summa cum laude in 2014. Dr. Rauen received honors and awards from the German Society of Neurology, German Society of Neurosurgery, International Neurotrauma Society, German Society of Neuroscience, European Academy of Neurology and European Brain Injury Consortium (EBIC). She is part of the ERA-Net Neuron CnsAflame TBI consortium on neuroinflammatory mechanisms following TBI and executive board member of the Women´s Brain Project to elucidate sex and gender differences following TBI.
University of Lucern, Switzerland
Antonella Santuccione Chadha
Women’s Brain Project, Roche Diagnostic, Switzerland
Antonella is the the Strategic Lead Oficer at WBP. She is a founder of WBP: She is a medical doctor with a wealth of experience in the field of Alzheimer’s disease and psychiatric disorders. She is a founder of the WBP. Until June 2018, she worked at the Swiss Regulatory Agency “Swissmedic” as a clinical reviewer in the eld of psychiatric and neurological disorders. Previously, she worked as a Postdoctoral Fellow and Resident at Swiss, Italian and German universities. She also gained experience in medical affairs for the pharma industry.
Annemarie Schumacher Dimech
President Women’s Brain Project, Switzerland
Annemarie serves as President of the Women’s Brain Project and she is a founder of the Women’s Brain Project. Her strong interest in mental health issues started in Malta where she read for a Bachelor’s degree in psychology. Later she studied health psychology at the University of Surrey (UK) and after that she spent a couple of years working with children with mental and/or physical disability. Annemarie Switzerland in 2005 and read for a PhD at the University of Bern. Annemarie worked as a researcher and teacher in the area of health and exercise psychology.
Silvina Catuara Solarz
Women’s Brain Project, Telefonica Innovation Alpha, Spain
Leader in Technology Application for Neuroscience and Mental Health at WBP
I am a Translational Neuroscientist with expertise in neuroplasticity processes in neurodevelopmental and neurodegenerative disorders.
After completing my B.Sc. in Biological and Health Psychology at the Autonomous University of Madrid and gaining experience in Clinical Neuropsychology and Cognitive Psychophysiology research techniques, I got my M.Sc. in Neuroscience at the School of Medicine at the Autonomous University of Madrid and the Cajal Institute. As part of my training, I performed my M.Sc. thesis under the supervision of Dr. Marta Nieto at the National Center for Biotechnology, investigating the role of histone demethylases in the epigenetic control during cortical neurodevelopment.
By that time, I developed a keen interest in understanding the neurobiological basis of cognition and behavior, and pursued my Ph.D. in Translational Neuroscience under the direction of Dr. Mara Dierssen at the Centre for Genomic Regulation and the Hospital del Mar Medical Research Institute. Throughout my studies I specialized in the molecular and cellular mechanisms underlying cognitive deficits and neurodegenerative processes affecting people with Down syndrome. My experimental and clinical research efforts were targeted on the development of multimodal therapeutic interventions for intellectual disabilities.
My current interests are focused on bridging Neuroscience and Technology to develop more efficient and personalized diagnostic and therapeutic tools for neurological disorders. I believe that to achieve a more precise understanding of brain disorders and to develop better medical interventions, a key step is to perform strong research programs focusing on gender differences. Therefore, I support and advocate for the mission of the Women’s Brain Project.
Health Policy Analyst at OECD, France
Royal Melbourne Hospital, Australia
Professor Szoeke is the Director of the Women’s Healthy Ageing Project. She led the research program in Neurodegenerative Diseases, Mental Disorders and Brain Health at the Australian Commonwealth Science and Industry Organisation (CSIRO) and then became a Clinical Consultant to CSIRO.
She a practicing neurologist with an honours degree in Genetics and Pharmacology, MBBS and FRACP with specialisation in Neurology and subspecialisation in Epileptology. She completed her PhD thesis in Epidemiology examining women’s healthy ageing and her post doctoral studies conducted between Stanford University and the University of Melbourne focussed on cognition.
She has been in clinical research for over a decade with over 300 publications, is a reviewer for national and international journals.
LifeStory Health, US
CEO Inn Ventis Ltd, Israel
Dr. Thomas Wilckens is a medical doctor and a serial entrepreneur. He serves as the CEO of InnVentis Ltd., with a focus on the convergence of multi-omics technologies with real-world clinical data and machine learning to enable Precision Medicine. The InnVentis technology platform combines data of unprecedented quality and depth with cutting-edge algorithms to create actionable insights such as cost-efficient sourcing of extremely high quality *omics analytics and clinical analytics, proprietary knowledge in machine learning and algorithm development, and stringent control of sample and data collection
with proprietary standard operation procedures. Dr. Wilckens is also the founder of the LinkedIn group Precision Medicine Insight. Prior to InnVentis, he was an associate at deep innovation GmbH, a boutique consultancy and spin-off of Vodafone Group R&D Germany. In 1998 he founded a drug discovery company as CEO/CSO with a focus on inflammatory and metabolic diseases. Thomas obtained his MD at the Ludwig-Maximilian University in Munich and started his research career as a scholar of the Max-Planck Society and the Max-Kade Foundation in New York. He held several post-doctorate positions at leading academic institutions before becoming an entrepreneur.
Aside from his work in Precision Medicine he developed a novel concept for value creation in research intensive industries; i.e. “Symbiotic Innovation”. With regard to this project Thomas was an associate at the GLORAD Research Center for Global R&D Management St. Gallen/Shanghai. Thomas is convinced that we will see a disruption of current diagnostics & therapeutic concepts and related business models. This paradigm shift will be induced by the advent of even greater communication and computing capabilities in concert with progress in omics and sensor technologies; i.e. Precision Medicine will ultimately be supported by algorithms for prevention, diagnostics and therapeutic decision making and become available anywhere 24/7.
Editor at The Lancet, UK